Bariatric Surgery Cuts Conversion to Diabetes Over Long-Term Follow-Up
By Lori Solomon HealthDay Reporter
MONDAY, June 17, 2024 -- Bariatric surgery significantly decreases the conversion from prediabetes to type 2 diabetes, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 9 to 13 in San Diego.
John Nguyen-Lee, M.D., from the Geisinger Medical Center in Danville, Pennsylvania, and colleagues evaluated the conversion from prediabetes to type 2 diabetes following bariatric surgery versus the conversion rate seen in a nonsurgical cohort. The analysis included 1,326 bariatric cases with prediabetes and propensity-matched nonsurgical controls from a primary care cohort.
The researchers found that the diabetes conversion rate at five, 10, and 15 years postoperatively was 1.8, 3.3, and 6.7 percent, respectively. In matched nonsurgical controls, the diabetes conversion rate was significantly higher at all time points (31.1, 51.4, and 68.7 percent, respectively; hazard ratio, 19.8). Compared with Roux-en-Y gastric bypass, individuals undergoing sleeve gastrectomy were more likely to convert to type 2 diabetes (hazard ratio, 4.01).
"This is the first study to analyze the long-term impact of metabolic and bariatric surgery on the potential progression of prediabetes and the impact is significant and durable," coauthor David Parker, M.D., also from the Geisinger Medical Center, said in a statement. "It demonstrates that metabolic surgery is as much a treatment as it is a prevention for diabetes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM
THURSDAY, April 17, 2025 -- Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.